JP2023541203A5 - - Google Patents
Info
- Publication number
- JP2023541203A5 JP2023541203A5 JP2023517268A JP2023517268A JP2023541203A5 JP 2023541203 A5 JP2023541203 A5 JP 2023541203A5 JP 2023517268 A JP2023517268 A JP 2023517268A JP 2023517268 A JP2023517268 A JP 2023517268A JP 2023541203 A5 JP2023541203 A5 JP 2023541203A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- stereoisomer
- acceptable salt
- compound according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079217P | 2020-09-16 | 2020-09-16 | |
| US63/079,217 | 2020-09-16 | ||
| PCT/US2021/050649 WO2022060973A1 (en) | 2020-09-16 | 2021-09-16 | Tyk2 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541203A JP2023541203A (ja) | 2023-09-28 |
| JP2023541203A5 true JP2023541203A5 (https=) | 2024-09-17 |
| JP7824938B2 JP7824938B2 (ja) | 2026-03-05 |
Family
ID=78086111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023517268A Active JP7824938B2 (ja) | 2020-09-16 | 2021-09-16 | Ｔｙｋ２阻害剤およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230357273A1 (https=) |
| EP (1) | EP4214215A1 (https=) |
| JP (1) | JP7824938B2 (https=) |
| KR (1) | KR20230069984A (https=) |
| CN (1) | CN117279922B (https=) |
| AU (1) | AU2021345181A1 (https=) |
| CA (1) | CA3192621A1 (https=) |
| IL (1) | IL301385A (https=) |
| WO (1) | WO2022060973A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| CA3245808A1 (en) * | 2022-03-16 | 2023-09-21 | Alumis Inc. | TYK2 INHIBITORS AND THEIR USES |
| CN119487037A (zh) * | 2022-03-16 | 2025-02-18 | 阿鲁米斯股份有限公司 | Tyk2抑制剂及其用途 |
| WO2023208244A1 (zh) * | 2022-04-29 | 2023-11-02 | 南京明德新药研发有限公司 | 大环类化合物及其应用 |
| JP2026512838A (ja) | 2023-03-31 | 2026-04-21 | 北京普祺医薬科技股▲分▼有限公司 | 大環化合物、医薬組成物及びその使用 |
| WO2024222807A1 (en) * | 2023-04-27 | 2024-10-31 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Novel macrocyclic heteroaryl derivatives as kinase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016287568B2 (en) | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| US10479793B2 (en) * | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| ES2902995T3 (es) * | 2016-10-07 | 2022-03-30 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| CN113348021B (zh) * | 2019-01-23 | 2025-07-11 | 武田药品工业株式会社 | Tyk2抑制剂和其用途 |
| JP2022519696A (ja) * | 2019-02-07 | 2022-03-24 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
| CA3132632A1 (en) * | 2019-03-11 | 2020-09-17 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| CA3134814A1 (en) | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
-
2021
- 2021-09-16 EP EP21789976.4A patent/EP4214215A1/en active Pending
- 2021-09-16 KR KR1020237012767A patent/KR20230069984A/ko active Pending
- 2021-09-16 IL IL301385A patent/IL301385A/en unknown
- 2021-09-16 WO PCT/US2021/050649 patent/WO2022060973A1/en not_active Ceased
- 2021-09-16 CN CN202180076687.5A patent/CN117279922B/zh active Active
- 2021-09-16 AU AU2021345181A patent/AU2021345181A1/en active Pending
- 2021-09-16 US US18/026,309 patent/US20230357273A1/en active Pending
- 2021-09-16 CA CA3192621A patent/CA3192621A1/en active Pending
- 2021-09-16 JP JP2023517268A patent/JP7824938B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541203A5 (https=) | ||
| JP7579402B2 (ja) | 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物 | |
| JP2022524974A5 (https=) | ||
| JP2022538228A5 (https=) | ||
| RU2472509C2 (ru) | Способ лечения артрита | |
| JP2021527638A5 (https=) | ||
| JP2019527731A (ja) | Ｈｂｖ感染の治療のための新規治療薬 | |
| AU2008307516B2 (en) | Method of treating polycystic kidney diseases with ceramide derivatives | |
| RU2012117398A (ru) | Бензоксазепиновые ингибиторы pi3 и способы применения | |
| RU2007124329A (ru) | ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| RU2004126671A (ru) | Гетероарилсоединения, полезные в качестве ингибиторов gsk-3 | |
| RU2004117887A (ru) | Ариланилиновые агонисты бета2 адренергических рецепторов | |
| JP2021514373A5 (https=) | ||
| JP2022522694A5 (https=) | ||
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2008517923A5 (https=) | ||
| JP2019501879A5 (https=) | ||
| RU2006124863A (ru) | Трициклические производные индолгидроксиэтиламина и их применение при лечении болезни альцгеймера | |
| JP2022510587A5 (https=) | ||
| RU2007116987A (ru) | Новые соединения | |
| JP2021519341A (ja) | グリコシド化合物、その調製方法、組成物、用途および中間体 | |
| CA3047146C (en) | Heterocyclic compounds and use thereof | |
| JP4045099B2 (ja) | ２０−ｈｅｔｅ産生酵素阻害剤 | |
| CN1177824C (zh) | 羟基甲脒衍生物及含有该衍生物的药物 |